Literature DB >> 3093417

Choice of optimum megavoltage for accelerators for photon beam treatment.

J S Laughlin, R Mohan, G J Kutcher.   

Abstract

Over three decades ago, the development of megavoltage accelerators revolutionized radiation oncology and provided the therapist with photons and electrons of any desired energy. The initial advantages cited for high energy photon therapy, listed below, have proved valid and accelerators have almost totally replaced orthovoltage units. Initially, it appeared that most of these cited advantages should continue to improve with increasing energy, and there has been an impetus for the production of ever higher megavoltage accelerators. Some of these advantages are reviewed in this paper. Also, recent investigations have indicated increasing diffuseness of the photon beam boundary with increasing energy because of lateral transport of electrons. The impact on treatment planning as a function of energy of the increase in volume dose due to the diffuseness of beam boundaries, "build-down" and "rebuild-up" effects in tissues at cavity and inhomogeneity interfaces, bone absorption, and photoneutron production are discussed. Consideration of the behavior of these parameters indicates that optimum photon energies have been achieved and that the impetus for higher megavoltages is unwarranted for most treatment. For many therapeutic applications, there are major advantages of 4 MV to 8 MV photon beams relative to 60Co gamma rays. For large lesions in the abdomen or pelvis there is an advantage to energies above those provided by 15 MV units. The various considerations above are discussed and summarized as a function of lesion site and megavoltage.

Entities:  

Mesh:

Year:  1986        PMID: 3093417     DOI: 10.1016/0360-3016(86)90277-4

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  7 in total

1.  Effect of photon-beam energy on VMAT and IMRT treatment plan quality and dosimetric accuracy for advanced prostate cancer.

Authors:  Marlies Pasler; Dietmar Georg; Holger Wirtz; Johannes Lutterbach
Journal:  Strahlenther Onkol       Date:  2011-11-29       Impact factor: 3.621

Review 2.  MR-guided radiation therapy: transformative technology and its role in the central nervous system.

Authors:  Yue Cao; Chia-Lin Tseng; James M Balter; Feifei Teng; Hemant A Parmar; Arjun Sahgal
Journal:  Neuro Oncol       Date:  2017-04-01       Impact factor: 12.300

3.  Dosimetric influence of photon beam energy and number of arcs on volumetric modulated arc therapy in carcinoma cervix: A planning study.

Authors:  Girigesh Yadav; Manindra Bhushan; Abhinav Dewan; Upasna Saxena; Lalit Kumar; Deepika Chauhan; Kothanda Raman; Swarupa Mitra; Mahammood Suhail
Journal:  Rep Pract Oncol Radiother       Date:  2016-10-17

4.  Dose-volume histogram comparison between static 5-field IMRT with 18-MV X-rays and helical tomotherapy with 6-MV X-rays.

Authors:  Akihiro Hayashi; Yuta Shibamoto; Yukiko Hattori; Takeshi Tamura; Michio Iwabuchi; Shinya Otsuka; Chikao Sugie; Takeshi Yanagi
Journal:  J Radiat Res       Date:  2015-01-20       Impact factor: 2.724

5.  The dosimetric significance of using 10 MV photons for volumetric modulated arc therapy for post-prostatectomy irradiation of the prostate bed.

Authors:  Henry Kleiner; Matthew B Podgorsak
Journal:  Radiol Oncol       Date:  2016-02-22       Impact factor: 2.991

6.  The dosimetric effect of mixed-energy IMRT plans for prostate cancer.

Authors:  Jong Min Park; Chang Heon Choi; Sung Whan Ha; Sung-Joon Ye
Journal:  J Appl Clin Med Phys       Date:  2011-11-15       Impact factor: 2.102

7.  Impact of nominal photon energies on normal tissue sparing in knowledge-based radiotherapy treatment planning for rectal cancer patients.

Authors:  Yuliang Huang; Sha Li; Haizhen Yue; Meijiao Wang; Qiaoqiao Hu; Haiyang Wang; Tian Li; Chenguang Li; Hao Wu; Yibao Zhang
Journal:  PLoS One       Date:  2019-03-07       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.